Journal issue - WANFANG MED ONLINE

You Position: Home > Journal issue

Chinese Journal of Oncology

Issue 3, 2024

Items 1-5 of 11

«Preious | of 3 | Next»

更正

Chinese Journal of Oncology, Volume 46, Issue 3,2024, Pages 268, doi:10.3760/cma.j.issn.0253-3766.2024.03.102

Expert consensus on clinical practice of EGFR exon20 insertion detection in non-small cell lung cancer in China (2024 edition)

Chinese Journal of Oncology, Volume 46, Issue 3,2024, Pages 179-188, doi:10.3760/cma.j.cn112152-20230905-00125

Mid-term analysis of prospective cohort study of rivaroxaban in preventing CRT in breast cancer

Chinese Journal of Oncology, Volume 46, Issue 3,2024, Pages 256-262, doi:10.3760/cma.j.cn112152-20231024-00218

Advances in the treatment of anti-HER-2 antibody drug conjugates in pan-tumor with low HER-2 expression

Chinese Journal of Oncology, Volume 46, Issue 3,2024, Pages 211-220, doi:10.3760/cma.j.cn112152-20231024-00227

Gemcitabine long-term maintenance chemotherapy benefits patients with survival: a multicenter, real-world study of advanced breast cancer treatment in China

Chinese Journal of Oncology, Volume 46, Issue 3,2024, Pages 249-255, doi:10.3760/cma.j.cn112152-20231024-00251

Items 1-5 of 11

«Preious | of 3 | Next»

2024:

2023:

2022:

2021:

2020:

2019:

2018:

2017:

2016:

2015:

2014:

2013:

2012:

2011:

2010:

2009:

2008:

2007:

2006:

2005:

2004:

2003:

2002:

2001:

2000:

1999:

1998:

Chinese Journal of Oncology

更正

Expert consensus on clinical practice of EGFR exon20 insertion detection in non-small cell lung cancer in China (2024 edition)

Mid-term analysis of prospective cohort study of rivaroxaban in preventing CRT in breast cancer

Advances in the treatment of anti-HER-2 antibody drug conjugates in pan-tumor with low HER-2 expression

Gemcitabine long-term maintenance chemotherapy benefits patients with survival: a multicenter, real-world study of advanced breast cancer treatment in China